In this episode, we dive into the buzz around cannabis rescheduling to Schedule 3, straight from a policy lover’s brain at THC Group. Expect a rollercoaster of insights: better medical research and patient care? Yes. Banking fixes and legalization? Not so fast. From pesticide woes in cannabis farming to the War on Drugs’ lingering scars, we wrestle with what’s won—and what’s still lost. Part rant, part revelation, this is one lawyer’s take on a thorny shift that’s more than meets the eye. Join us for the real talk.